Compare Endeavour Silver Corp (EXK) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Endeavour Silver Corp vs Novartis AG — how do they compare? Endeavour Silver Corp trades at $7.54 (market cap $2.36B), while Novartis AG trades at $152.31 (market cap $287.66B). The key difference: Novartis AG is far larger — about 121.9× Endeavour Silver Corp's market cap, and Novartis AG pays a 3.14% dividend while Endeavour Silver Corp pays none. Which is the better fit depends on your goals.
| EXK | NVS | |
|---|---|---|
Market Cap | $2.36B | $287.66B |
Sector | Basic Materials | Health |
52-Week High | $14.12 | $168.62 |
52-Week Low | $4.96 | $113.50 |
Enterprise Value | $2.36B | $327.68B |
Dividend Yield | — | 3.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Endeavour Silver (EXK) trades at $7.625, down 5.63% today, with a bearish technical signal from moving averages. The company reported a Q1 2026 earnings beat of $0.21 per share versus $0.10 expected, driven by record production. However, 2025 financials show a net loss of $119.1 million despite revenue growth, with negative profit margins and ROE. Analyst consensus is strongly bullish with 11 buy ratings.
Outlook hinges on operational execution and silver price trends. Investment opportunity exists from production growth and potential margin improvement, but risks include sustained negative profitability, high debt-to-asset ratio, and commodity price volatility. Cash flow trends show improvement into 2026, supporting near-term stability.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Endeavour Silver Corp
Endeavour Silver is a mid-tier precious metals mining company. It operates silver-gold mines in Mexico and is focused on growing its production and reserves through exploration and the development of new mining projects.
Read more on EXK →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
